Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Puma Biotechnology (PBYI) Cash & Current Investments (2017 - 2025)

Puma Biotechnology's Cash & Current Investments history spans 9 years, with the latest figure at $97.5 million for Q4 2025.

  • For Q4 2025, Cash & Current Investments fell 3.4% year-over-year to $97.5 million; the TTM value through Dec 2025 reached $97.5 million, down 3.4%, while the annual FY2025 figure was $97.5 million, 3.4% down from the prior year.
  • Cash & Current Investments reached $97.5 million in Q4 2025 per PBYI's latest filing, up from $55.6 million in the prior quarter.
  • In the past five years, Cash & Current Investments ranged from a high of $109.0 million in Q2 2021 to a low of $55.6 million in Q3 2025.
  • Average Cash & Current Investments over 5 years is $84.9 million, with a median of $86.3 million recorded in 2021.
  • Peak YoY movement for Cash & Current Investments: crashed 44.25% in 2022, then soared 50.47% in 2024.
  • A 5-year view of Cash & Current Investments shows it stood at $72.0 million in 2021, then grew by 12.63% to $81.1 million in 2022, then increased by 18.34% to $95.9 million in 2023, then increased by 5.24% to $101.0 million in 2024, then dropped by 3.4% to $97.5 million in 2025.
  • Per Business Quant, the three most recent readings for PBYI's Cash & Current Investments are $97.5 million (Q4 2025), $55.6 million (Q3 2025), and $56.8 million (Q2 2025).